CHM
vs
C
CANF
CHM
Over the past 12 months, CHM has outperformed CANF, delivering a return of -71% compared to the CANF's 89% drop.
Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
Smart Verdict
AI-Powered
Let AI Decide.
CHM
Valuation Comparison
| Company | Last Price | Intrinsic Value | DCF Value | Relative Value | Wall St Target | ||
|---|---|---|---|---|---|---|---|
|
Chimeric Therapeutics Ltd
ASX:CHM
|
0.002
AUD
|
|||||
|
C
|
Can Fite Biopharma Ltd
TASE:CANF
|
688
ILS
|
|||||
Compare the stock's valuation with its competitors.
Growth Comparison
Growth Over Time
CHM, CANF
Compare company's financials with its competitors.
| Company | LTM | Historical Growth | Growth Streak | % Positive Years | Max Drawdown | Volatility | Forecasted Growth | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3 Years | 5 Years | 10 Years | 1 Year | 3 Years | ||||||||
|
Chimeric Therapeutics Ltd
Revenue
|
|||||||||||
|
C
|
Can Fite Biopharma Ltd
Revenue
|
|||||||||||
All metrics are calculated based on data from the last 10 years.
Compare company's financials with its competitors.
Profitability Comparison
Free Cash Flow
CHM, CANF
Compare company's free cash flow with its competitors.
| Company | LTM | Average | Historical Growth | FCF Margin | Conversion | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| 3 Years | 5 Years | 3 Years | 5 Years | 10 Years | ||||||
|
Chimeric Therapeutics Ltd
ASX:CHM
|
|||||||||
|
C
|
Can Fite Biopharma Ltd
TASE:CANF
|
|||||||||
Compare company's free cash flow with its competitors.
Gross Margin
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
Chimeric Therapeutics Ltd | ||||
|
C
|
Can Fite Biopharma Ltd | ||||
Operating Margin
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
Chimeric Therapeutics Ltd | ||||
|
C
|
Can Fite Biopharma Ltd | ||||
Net Margin
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
Chimeric Therapeutics Ltd | ||||
|
C
|
Can Fite Biopharma Ltd | ||||
FCF Margin
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
Chimeric Therapeutics Ltd | ||||
|
C
|
Can Fite Biopharma Ltd | ||||
ROE
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
Chimeric Therapeutics Ltd | ||||
|
C
|
Can Fite Biopharma Ltd | ||||
ROA
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
Chimeric Therapeutics Ltd | ||||
|
C
|
Can Fite Biopharma Ltd | ||||
ROIC
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
Chimeric Therapeutics Ltd | ||||
|
C
|
Can Fite Biopharma Ltd | ||||
ROCE
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
Chimeric Therapeutics Ltd | ||||
|
C
|
Can Fite Biopharma Ltd | ||||
Solvency Comparison
Compare company's equity waterfall with its competitors.
Stocks Performance
Stocks Performance
CHM, CANF
Performance Gap
CHM, CANF
Performance By Year
CHM, CANF
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
| FR |
|
Pharnext SCA
OTC:PNEXF
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
|
| US |
S
|
Seagen Inc
F:SGT
|